Ola Kleveland
St Olav's University Hospital(NO)
Publications by Year
Research Areas
Acute Myocardial Infarction Research, Atherosclerosis and Cardiovascular Diseases, Cardiac Fibrosis and Remodeling, Cytokine Signaling Pathways and Interactions, Coronary Interventions and Diagnostics
Most-Cited Works
- → Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction(2021)383 cited
- → Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial(2016)370 cited
- → Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction(2017)54 cited
- → Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial(2022)48 cited
- → Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis(2023)46 cited
- → Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)(2019)44 cited
- → Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction(2018)34 cited
- → IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction(2018)28 cited
- → Novel Insights Into the Effects of Interleukin 6 Antagonism in Non–ST‐Segment–Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform(2020)25 cited
- → Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction(2018)18 cited